PDF herunterladen
CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2016; 74(06): 462-469
DOI: 10.1590/0004-282X20160067
ARTICLES

Botulinum neurotoxin type-A when utilized in animals with trigeminal sensitization induced a antinociceptive effect

Neurotoxina botulínica do tipo-A quando utilizada em animais com sensibilização trigeminal induz efeito antinociceptivo
Elcio J Piovesan
1   Universidade Federal do Paraná, Hospital das Clínicas, Serviço de Neurologia, Curitiba PR, Brasil;
2   Universidade Federal do Paraná, Departmento de Ciências da Saúde, Laboratório Experimental, Curitiba PR, Brasil;
,
Michael Oshinsky
3   Thomas Jefferson University, Jefferson Headache Center, Philadephia PA, USA.
,
Stephen Silberstein
3   Thomas Jefferson University, Jefferson Headache Center, Philadephia PA, USA.
,
Pedro Andre Kowacs
1   Universidade Federal do Paraná, Hospital das Clínicas, Serviço de Neurologia, Curitiba PR, Brasil;
,
Edison Matos Novak
1   Universidade Federal do Paraná, Hospital das Clínicas, Serviço de Neurologia, Curitiba PR, Brasil;
,
Lineu Cesar Werneck
1   Universidade Federal do Paraná, Hospital das Clínicas, Serviço de Neurologia, Curitiba PR, Brasil;
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
  Lizenzen und Reprints

ABSTRACT

Purpose of the study was evaluate the possible antinociceptive effect of botulinum neurotoxin type-A (BoNT/A) in an experimental model of trigeminal neuralgia.

Method Neuropathic pain was induced by surgical constriction of the infraorbital nerve in rats. A control group underwent a sham procedure consisting of surgical exposure of the nerve. Subgroups of each group received either BoNT/A or isotonic saline solution. The clinical response was assessed with the -20°C test. Animals that underwent nerve constriction developed sensitization; the sham group did not.

Results The sensitization was reversed by BoNT/A treatment evident 24 hours following application. Pronociceptive effect was observed in the sham group following BoNT/A.

Conclusion BoNT/A has an antinociceptive effect in sensitized animals and a pronociceptive effect in non-sensitized animals.

RESUMO

A proposta do estudo foi avaliar o efeito antinociceptivo da neurotoxina botulínica do tipo A (BoNT/A) em um modelo experimental de nevralgia trigeminal.

Método O grupo estudo foi obtido através da constrição do nervo infraorbital em ratos e o grupo controle pela simples exposição deste nervo. Cada um dos grupos foram subdivididos de acordo com o tratamento realizado após a intervenção cirurgica: solução salina isotçnica ou BoNT/A. A resposta terapêutica foi avaliada através do teste de -20°C.

Resultados Animais com constrição do nervo desenvolveram uma sensibilização nociceptiva quando comparados ao grupo controle. Ela foi revertida após 24 horas utilizando BoNT/A. O efeito pronociceptivo foi observado no grupo controle após a administração de BoNTA.

Conclusão BoNT/A apresenta um efeito antinociceptivo em animais sensibilizados e pronociceptivo em animals não sensibilizados.

analgesics - botulinum toxins - facial pain - trigeminal neuralgia
analgésicos - toxinas botulínicas - dor facial - nervo infraorbital - neuralgia do trigêmeo

Support:

Support: The study was supported by the Coordenção de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).




Publikationsverlauf

Eingereicht: 06. Oktober 2015

Angenommen: 01. April 2016

Artikel online veröffentlicht:
06. September 2023

© 2023. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3 rd edition (beta version). Cephalalgia. 2013;33(9):629-808. doi:10.1177/0333102413485658
  • 2 Truini A, Galeotti F, Cruccu G. New insight into trigeminal neuralgia. J Headache Pain. 2005;6(4):237-9. doi:10.1007/s10194-005-0195-9
  • 3 Rozen TD, Capobianco DJ. Cranial neuralgias and other causes of facial pain. In: Silberstein SD, Lipton R, Dodick DW, editors. Wolff’s Headache and other head pain. 8th ed. New York: Oxford:, 2008. p. 633-50.
  • 4 Cruccu G, Gronseth G, Alksne J, Argoff C, Brainin M, Burchiel K et al. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008;15(10):1013-28. doi:10.1111/j.1468-1331.2008.02185.x
  • 5 Marinelli S, Luvisetto S, Cobianchi S, Makuch W, Obara I, Mezzaroma E et al. Botulinum neurotoxin type A counteracts neuropathic pain and facilitates functional recovery after peripheral nerve injury in animal models. Neuroscience. 2010;171(1):316-28. doi:10.1016/j.neuroscience.2010.08.067
  • 6 Matak I, Bach-Rojecky L, Filipović B, Lacković Z. Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience. 2011;186:201-7. doi:10.1016/j.neuroscience.2011.04.026
  • 7 Restani L, Novelli E, Bottari D, Leone P, Barone I, Galli-Resta L et al. Botulinum neurotoxin A impairs neurotransmission following retrograde transynaptic transport. Traffic. 2012;13(8):1083-9. doi:10.1111/j.1600-0854.2012.01369.x
  • 8 Filipović B, Matak I, Bach-Rojecky L, Lacković Z. Central action of peripherally applied botulinum toxin type A on pain and dural protein extravasation in rat model of trigeminal neuropathy. PloS One. 2012;7(1):e29803. doi:10.1371/journal.pone.0029803
  • 9 Marinelli S, Vacca V, Ricordy, Uggenti C, Tata A, Luvisetto S et al. The analgesic effect on neuropathic pain of retrogradely transported botulinum neurotoxin A involves Schwann cells and Astrocytes. PloS One. 2012;7(10):47977. doi:10.1371/journal.pone.0047977
  • 10 Kumada A, Matsuka Y, Spigelman I, Maruhama K, Yamamoto Y, Neubert JK et. al. Intradermal injection of Botulinum toxin type A alleviates infraorbital nerve constriction-induced thermal hyperalgesia in an operant assay. J Oral Rehabil. 2012;39(1):63-72. doi:10.1111/j.1365-2842.2011.02236.x
  • 11 Piovesan EJ, Teive HG, Kowacs PA, Della Coletta MV, Werneck LC, Silberstein SD. An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology. 2005;65(8):1306-8. doi:10.1212/01.wnl.0000180940.98815.74
  • 12 Wu CJ, Lian YJ, Zheng YK, Zhang HF, Chen Y, Xie NC et al. Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia. 2012;32(6):443-50. doi:10.1177/0333102412441721
  • 13 Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE et al.. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-73. doi:10.1111/j.1526-4610.2011.01990.x
  • 14 Vos BP, Strassman AM, Maciewicz RJ. Behavioral evidence of trigeminal neuropathic pain following chronic constriction injury to the rat’s infraorbital nerve. J Neurosci. 1994;14(5):2708-23.
  • 15 Chichorro JG, Zampronio AR, Souza GEP, Rae GA. Orofacial cold hyperalgesia due to infraorbital nerve constriction injury in rats: reversal by endothelin receptor antagonists but non-steroidal anti-inflammatory drugs. Pain. 2006;123(1-2):64-74. doi:10.1016/j.pain.2006.02.010
  • 16 Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107(1-2):125-33. doi:10.1016/j.pain.2003.10.008
  • 17 Piovesan EJ, Leite LS, Teive HG, Kowacs PA, Mulinari RA, Radunz V, et al. Botulinum toxin type-A effect as a preemptive treatment in a model of acute trigeminal pain: a pre-clinical double-blind and placebo-controlled study. Arq Neuropsiquiatr. 2011;69(1):56-63. doi:10.1590/S0004-282X2011000100012
  • 18 Kitamura Y, Matsuka Y, Spigelman I, Ishihara Y, Yamamoto Y, Sonoyama W et al. Botulinum toxin type a (150 kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction. Neuroscience. 2009;159(4):1422-9. doi:10.1016/j.neuroscience.2009.01.066
  • 19 Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000;38(2):245-58. doi:10.1016/S0041-0101(99)00153-1
  • 20 Meng J, Wang J, Lawrence G, Dolly JO. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci. 2007;120(16):2864-74. doi:10.1242/jcs.012211
  • 21 Meng J, Ovsepian SV, Wang J, Pickering M, Sasse A, Aoki KR et al. Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J Neurosci. 2009;29(15):4981-92. doi:10.1523/JNEUROSCI.5490-08.2009
  • 22 Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt-Nielsen L. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain. 2009;141(1-2):60-9. doi:10.1016/j.pain.2008.10.005
  • 23 Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol. 2008;64(3):274-83. doi:10.1002/ana.21427
  • 24 Yuan RY, Sheu JJ, Yu JM, Chen WT, Tseng IJ, Chang HH et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology. 2009;72(17):1473-8. doi:10.1212/01.wnl.0000345968.05959.cf
  • 25 Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring J et al. Botulinum neurotoxin type A for treatment of chronic migraine: pooled analysis of the PREEMPT clinical program 32-week open-label phase. Cephalalgia. 2009;29(Suppl 1):7-8.
  • 26 Piovesan EJ, Teive HG, Kowacs PA, Silva LL, Werneck LC. Botulinum neurotoxin type-A for primary stabbing headache: an open study. Arq Neuropsiquiatr. 2010;68(2):212-5. doi:10.1590/S0004-282X2010000200011
  • 27 Wu CJ, Lian YJ, Zheng YK, Zhang HF, Chen Y, Xie NC et al. Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia. 2012;32(6):443-50. doi:10.1177/0333102412441721
  • 28 Morenilla-Palao C, Planells-Cases R, García-Sanz N, Ferrer-Montiel A. Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem. 2004;279(24):25665-72. doi:10.1074/jbc.M311515200
  • 29 Linde M, Hagen K, Salvesen Ø, Gravdahl GB, Helde G, Stovner LJ. Onabotulinum toxin A treatment of cervicogenic headache: a randomized, double-blind, placebo-controlled crossover study. Cephalalgia. 2011;31(7):797-807. doi:10.1177/0333102411398402
  • 30 Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache. 2007;47(4):486-99. doi:10.1111/j.1526-4610.2006.00624.x